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Objective: Although paclitaxel is widely used as a systemic agent for the treatment
of solid tumors, limited information is available concerning administration of this
taxane by regional techniques. The present study was undertaken to evaluate the
pharmacokinetics and acute toxicity of paclitaxel administered by hyperthermic
retrograde isolated lung perfusion techniques to ascertain its potential for the
regional therapy of unresectable pulmonary neoplasms.
Methods: Adult sheep underwent 90 minutes of retrograde isolated lung perfu-
sion with escalating doses of paclitaxel and moderate hyperthermia using a
protein-free, oxygenated extracorporeal circuit and a steady perfusion pressure
of 14 to 16 mm Hg. An additional animal received paclitaxel by means of 1-hour
central venous infusion. Paclitaxel concentrations in lung tissues, perfusates,
and systemic circulation were determined by high-performance liquid chromo-
tography techniques. Cytotoxicity of paclitaxel in cancer cells and in normal
human bronchial epithelial cells was evaluated in vitro using 4, 5-dimethyl-
thiazo-2-yl-25-dipagnyl tetrazolium bromide assays. Lung tissues were exam-
ined by hematoxylin-and-eosin techniques.
Results: Paclitaxel concentrations (maximum concentration and area under the
plasma concentration time curve) in perfused tissues increased with escalating
perfusate doses. Uptake of drug into lung parenchyma appeared saturable at high
paclitaxel exposure; a substantial pharmacokinetic advantage was observed.
Paclitaxel concentrations in systemic circulation were undetectable or exceed-
ingly low after perfusion. Histopathologic examination of lung tissues harvested
3 hours after completion of isolated lung perfusion revealed no immediate
toxicity, even at a paclitaxel exposure 20-fold higher than that achievable after
1 hour of intravenous administration at the maximum tolerable dose in human
subjects. Moderate hyperthermia enhanced paclitaxel-mediated cytotoxicity 5-
to 100-fold in cultured cancer lines. No paclitaxel toxicity was observed in
cultured normal human bronchial epithelial cells after exposure to paclitaxel
under normothermic or hyperthermic conditions.
Conclusions: These data support further evaluation of paclitaxel administered by
hyperthermic retrograde isolated lung perfusion techniques for the treatment of
unresectable malignant pulmonary tumors.
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Nearly one third of all patients with ex-trathoracic malignant tumors have pulmo-nary metastases. Many patients, particu-larly those with soft tissue sarcomas, dieof metastatic disease confined to thelungs. Treatment of these individuals re-
mains controversial.1
Nearly 60 years ago, Alexander and Haight2 reported
prolongation of survival in 12 patients undergoing pulmo-
nary metastasectomy; the algorithms that they used to select
patients for resection remain valid today. Current studies
have confirmed the role of surgical intervention in patients
with pulmonary metastases and have demonstrated that
survival correlates with completeness of resection, histol-
ogy, and number of pulmonary nodules.3 In general, pa-
tients with metastatic melanomas do poorly, despite appar-
ently complete resections (5-year survival of 25%),
whereas those with germ-cell cancers tend to do quite well
after pulmonary metastasectomy (5-year survival of approx-
imately 60%). Patients with metastases from epithelial ma-
lignant tumors have intermediate survivals. Collectively,
these data indicate that some patients can be salvaged by
metastasectomy alone; however, the majority of individuals
either present with or subsequently develop inoperable dis-
ease.
Whereas the role of systemic chemotherapy is debat-
able,4 it is conceivable that high doses of cytotoxic agents
administered by isolated lung perfusion techniques may
prove efficacious for the treatment of unresectable pulmo-
nary malignancies. Doxorubicin, cisplatin, and tumor ne-
crosis factor have been administered by antegrade isolated
lung perfusion; however, their efficacies and toxicities in
this context have not been fully defined.5-8 In the present
study we used a sheep model to evaluate the feasibility of
hyperthermic retrograde isolated lung perfusion, and the
pharmacokinetics of paclitaxel administered by these tech-
niques. Herein we report a profound pharmacokinetic ad-
vantage for paclitaxel administered in this manner, and
demonstrate significant enhancement of paclitaxel-mediated
cytotoxicity by moderate hyperthermia in cultured cancer
lines but not in normal bronchial epithelial cells. These data
support the evaluation of paclitaxel administered by means
of isolated lung perfusion for the treatment of inoperable
pulmonary malignancies.
Materials and Methods
Administration of Paclitaxel by Means of Isolated
Lung Perfusion or Intravenous Infusion
All animal experiments were approved by the National Cancer
Institute (NCI) Animal Care and Use Committee and were in strict
compliance with the “Guide for the Care and Use of Laboratory
Animals.” The NCI is accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care International.
Adult sheep received 1 mg of atropine sulfate intramuscularly
1 hour before sedation, with 10 mg of diazepam administered
intravenously. The left external jugular vein was cannulated for
venous access, and anesthesia was induced with approximately 20
mg/kg pentobarbital administered intravenously (given to effect).
The animals were intubated with a single-lumen endotrachial tube
and maintained under general anesthesia with an average of 2.5%
isofluorane and 1 L/min oxygen flow. Dexamethasone (20 mg) and
diphenhydramine (50 mg) were administered intravenously. The
left chest was prepared and entered through a lateral thoracotomy
through the fifth intercostal space. The descending aorta was
cannulated for arterial line placement. The inferior pulmonary
ligament was incised, and the left mainstem bronchus was dis-
sected free of adjacent nodal tissues and encircled with an umbil-
ical tape. Bronchial arteries were ligated at the tracheobronchial
angle. The pericardium was incised, and the ligamentum arterio-
sum was divided; the left main pulmonary artery and the left
superior and inferior pulmonary veins were isolated and encircled
with vascular loops. Heparin (300 U/kg) was administered intra-
venously, and vascular clamps were placed on the proximal left
pulmonary artery and across the left atrium to isolate the left lung.
A DLP retrograde cardioplegia cannula (DLP Medtronic, Grand
Rapids, Mich) was inserted into the isolated left atrium, and a 20F
angled DLP venous cannula was placed into the left main pulmo-
nary artery; the cannulas were connected to a closed, oxygenated
extracorporeal circuit, silicone bonded to minimize leaching of
di-2-ethylhexyphthalate during the perfusion. After partial infla-
tion of the left lung, the left bronchus was clamped to provide
continuous positive airway pressure of 5 to 10 mm Hg during the
perfusion. The previously ligated bronchial arteries were
transected to allow back bleeding from the left lung. One liter of
Ringer’s lactate containing 250 g of prostaglandin E1 (Prostin
VR; Pharmacia, Kalamazoo, Mich) was infused over 5 minutes in
a retrograde manner through a single pass to flush the lung and
dilate the pulmonary vasculature; effluent was discarded. A 3-L
protein-free perfusate consisting of Ringer’s lactate containing
allogeneic packed red blood cells (final hematocrit, 10 g/dL) and
the appropriate dose of paclitaxel (Bristol Myers Squibb, Evans-
ville, Ind) was infused continuously in a retrograde manner under
moderate hyperthermia (perfusate temperature, 39.5°C). Effluent
from transected bronchial vessels was returned to the circuit for
reinfusion. Flow rates were adjusted to maintain a perfusion pres-
sure within the pulmonary veins of 14 to 16 mm Hg, as measured
with a pressure transducer connected to the cardioplegia cannula.
Perfusion continued in this manner for 90 minutes, during which
the total volume of perfusate typically circulated through the lung
at least 9 times. After the perfusion, the lung was flushed with 1 L
of Ringer’s lactate, cannulas were removed, and vessels were
repaired. Ventilation and perfusion were reestablished in the per-
fused lung, and the animal was maintained under general anesthe-
sia for an additional 3 hours to enable collection of samples for
pharmacokinetic and histopathologic analysis. Animals were
then put to death under anesthesia by NCI veterinary staff.
One sheep received paclitaxel intravenously by means of cen-
tral venous infusion over 1 hour after left thoracotomy. The sheep
was maintained for 7 hours under general anesthesia for collection
of lung and peripheral blood samples and subsequently put to
death as described above.
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Analysis of Paclitaxel Levels in Perfusates, Plasma,
and Lung Tissues
Perfusate samples were collected before addition of paclitaxel to
the pump, immediately before perfusion, and at 5, 10, 15, 20, 30,
45, 60, and 90 minutes after initiation of perfusion. Peripheral
blood samples were collected at 0, 5, 30, 60, 90, 120, 150, and 270
minutes relative to initiation of perfusion, or at 0, 30, 45, 60, 90,
120, 150, 180, 210, 240, 270, 300, 360, and 420 minutes relative
to initiation of intravenous infusion. Perfusate and blood samples
were collected in heparinized tubes, placed on ice until completion
of the procedure, and then centrifuged; plasma was removed and
stored at –70°C. Lung tissue samples were collected at 0, 5, 30, 60,
90, 100, 120, 150, and 270 minutes relative to initiation of perfu-
sion or at 0, 30, 45, 60, 90, 120, 180, 240, and 270 minutes relative
to initiation of intravenous infusion. Tissue samples were imme-
diately snap-frozen in liquid nitrogen, and stored at –70°C until
prepared for analysis as previously described,9 with modification.
Briefly, after addition of 1 mL of 0.9% NaCl, thawed lung tissue
samples were disrupted with a homogenizer. Paclitaxel was recov-
ered from tissue homogenates, as well as perfusate and plasma
samples by means of acetylnitrile extraction, and analyzed with
reverse-phase high-performance liquid chromatography,10 with a
lower limit of detection of 20 ng/mL. Standard curves were con-
structed by adding appropriate amounts of paclitaxel (100-1000
ng) to 300 mg of nonperfused lung tissue, followed by extraction
and analysis as described above. Standard curves for perfusate and
plasma samples were constructed by using analogous techniques.
Pharmacokinetic Analysis
Pharmacokinetic parameters were calculated by using noncom-
partmental analysis. The terminal elimination rate constant (Ke)
was determined from linear regression analysis. The plasma elim-
ination half-life (t1⁄2) was calculated as follows:
t1⁄2  0.693/Ke.
The area under the plasma concentration time curve (AUC) for
each animal was calculated by using the linear trapezoidal method
from time 0 to the last concentration time point obtained (AUC0-t),
and extrapolated to infinity by dividing the last concentration by
the terminal elimination rate constant. The maximum concentra-
tion (Cmax) for perfusate was obtained at time 0. Cmax values for
lung tissue and plasma were obtained from observed experimental
values.
Histologic Analysis of Lung Tissues
Three hours after completion of the lung perfusion, tissue samples
were obtained from the perfused and the contralateral, unperfused
lung. Tissue samples were formalin fixed, paraffin embedded,
sectioned, and stained with hematoxylin-eosin. The slides were
evaluated in a blinded manner by a senior pathologist (P.H.D.) for
evidence of acute lung injury.
Cell Lines and In Vitro Proliferation Assays
The non–small cell lung cancer lines H1299, H460, and H358; the
melanoma lines SK-mel-5 and 586 mel; and the fibrosarcoma cell
line HT1080 were available in tissue-culture banks at the NCI.
Normal human bronchial epithelial cells were purchased from
Clonetics (Bio Whittaker, Inc, Walkersville, Md). Cell lines were
maintained in RPMI medium supplemented with 10% fetal calf
serum and antibiotics. Paclitaxel was purchased from Bristol My-
ers Squibb. 4, 5-Dimethylthiazo-2-yl-25-dipagnyl tetrazolium bro-
mide was obtained from Sigma (St Louis, Mo). For in vitro
proliferation assays, cells were seeded in flat-bottomed 96-well
microtiter plates at densities optimized for each cell line. After
overnight incubation, cells were exposed to varying doses of
paclitaxel at 37°C or 39.5°C for 90 minutes. After 90-minute drug
treatment, paclitaxel was removed, media was replenished, and
cells were incubated for 3 days at 37°C. Cell viability was quan-
titated by 4, 5-dimethylthiazo-2-yl-25-dipagnyl tetrazolium bro-
mide colorimetric assays.11 Dose-response curves for cells treated
with paclitaxel were plotted as a fraction of viable cells relative to
cells grown in normal media. Paclitaxel 50% inhibitory concen-
tration values for cells treated under normothermia or hyperther-
mia were derived from the respective dose-response curves. Re-
duction of paclitaxel 50% inhibitory concentration values in cells
treated with the drug at 39.5°C indicated an increase in the cellular
responsiveness to paclitaxel under hyperthermic conditions.
Statistical Analysis
Data from proliferation assays were expressed as means  SD.
Two-tailed Student t tests were performed with a Prism 2.0 soft-
ware package from Graph Pad Software (San Diego, Calif) to
determine the significance of treatment effects in cultured cells
under normothermic or hyperthermic conditions.
Results
Retrograde isolated lung perfusion was successfully com-
pleted in 10 sheep. The first animal received perfusate
without paclitaxel; as assessed by fluorescein techniques,
perfusion appeared quite uniform in the isolated lung (data
not shown). On the basis of these initial observations, an
additional 9 sheep underwent isolated lung perfusion with
paclitaxel. Depending on the size of the animals, flow rates
typically ranged between 300 and 500 mL/min. Two heat
exchangers were used to maintain hyperthermia in the lung
(average temperature, 38.5°C-39.5°C, as measured with
temperature probes in the upper and lower lobes). During
the procedure, perfusate emanated across the visceral
pleura, and retrograde bronchial arterial flow was clearly
evident. Although not precisely quantitated, this effluent,
which was continually returned to the pump, was at least
several hundred milliliters.
Concentration-time profiles and pharmacokinetic param-
eters for paclitaxel perfusates are summarized in Figure 1
and Table 1, respectively. The Cmax of paclitaxel in perfus-
ates increased with dose; however, the Cmax at a dose of 2
mg (lowest dose) was lower than expected (0.23 vs 0.6
g/mL), possibly due to nonspecific binding of paclitaxel to
the extracorporeal circuit. At higher doses, the Cmax was
consistent with doses administered. The elimination rate
constant decreased, and elimination half-life increased with
escalating drug dose. Paclitaxel concentrations in perfusates
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decreased in a biexponential manner. At the high doses, the
slope of the elimination phase was diminished, suggesting
that the uptake of paclitaxel into pulmonary tissues was
saturable.
Concentration-time profiles and pharmacokinetic param-
eters for paclitaxel in lung tissues are represented in Figure
2 and Table 2, respectively. Paclitaxel concentrations in
lung tissues increased nonlinearly with escalating dose and
peaked between 60 and 90 minutes; tissue levels rapidly
declined during washout. Lung tissue Cmax and AUC in-
creased disproportionately with dose, gradually approach-
ing a plateau. The average Cmax (50 ng/mg) in lung tissues
obtained when 200 mg (78 mol/L) of paclitaxel was used
in the perfusion was approximately 2-fold higher than that
observed after systemic infusion of the same dose of pac-
litaxel over 1 hour; tissue AUCs under these conditions
were relatively comparable (Table 2). The plasma Cmax
(15.1 g/mL) and AUC (26 to 30 g  h–1  mg–1) observed
after a 1-hour infusion of 200 mg of paclitaxel (approxi-
mately 150 mg/m2) in sheep were comparable with those
reported by Maier-Lenz and colleagues12 after a 1-hour
infusion of 225 mg/m2 (the maximum tolerated dose) in
cancer patients. When the dose of paclitaxel in the perfusate
was increased to 800 mg (approximately 320 mol/L), the
Cmax of paclitaxel in perfused tissues was approximately 86
Figure 1. Paclitaxel concentration-time profile in perfusates.
Doses are 2 mg (squares), 20 mg (diamonds), 40 mg (inverted
triangles), 200 mg (triangles), and 800 mg (circles).
TABLE 1. Pharmacokinetic parameters of paclitaxel in per-
fusates
Dose (mg) Cmax (g/mL) Ke (h
1) T1/2 (h)
AUC(0-1.5)
(g  h1  mL1)
2 0.23 1.11 0.62 0.09
2 0.20 1.56 0.44 0.02
20 4.26 0.69 1.01 1.95
40 12.36 0.45 1.53 7.07
40 11.53 0.41 1.71 6.99
200 65.87 0.19 3.63 70.00
200 72.15 0.12 5.68 73.70
800 307.00 0.09 7.57 348.00
800 272.59 0.10 6.93 356.87
Figure 2. Paclitaxel concentration-time profiles in lung tissues
after perfusion and 1-hour intravenous paclitaxel infusion. Pac-
litaxel was administered by isolated lung perfusion at doses of
200 mg (filled squares) and 800 mg (filled circles) and intrave-
nously at a dose of 200 mg (open squares).
TABLE 2. Cmax and AUC of paclitaxel in lung tissues after
perfusion or intravenous infusion
Dose (mg) Cmax (ng/mg)
AUC(0-4.5)
(g  h1  mg1)
Perfusion 2 1.96 7.04
2 2.04 5.02
20 11.9 26.05
40 14.5 32.9
40 15.6 26.24
200 60.4 96.7
200 41.4 60.8
800 85.8 165.2
800 94.3 202.4
Intravenous infusion 200 25.4 73
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ng/mL, and the AUC was approximately 165 ng  h–1  mg–1
(Figure 2 and Table 2).
Paclitaxel concentrations in the systemic circulation
were undetectable at all perfusate doses during the isolated
lung perfusion (Table 3). After restoration of circulation to
the perfused lung, systemic levels were either undetectable
or extremely low; no drug was detected in any systemic
blood sample after perfusion with 2, 20, or 40 mg of
paclitaxel. After 200- and 800-mg perfusions, paclitaxel
could be detected after the washout period but quickly
disappeared. Cmax in plasma after these perfusions (approx-
imately 0.10 and 0.19 g/mL, respectively) was signifi-
cantly lower than that observed after a 200-mg intravenous
infusion (15 g/mL). These data indicate that most of the
paclitaxel was removed by the postperfusion flush, and that
retained drug was not rapidly released from the lung into the
systemic circulation (Figure 2 and Table 3).
No severe immediate clinical toxicity was evident in
these animals; oxygen saturations were approximately 93%
to 95% after perfusion, and only mild, transient bronchor-
rhea was observed in animals perfused with high doses of
paclitaxel once ventilation resumed in the perfused lung.
Histopathologic examination of lung tissues obtained 3
hours after completion of the isolated lung perfusion re-
vealed no evidence of pulmonary hemorrhage, alveolar
edema, or interstitial thickening, even at a paclitaxel expo-
sure 20-fold higher (320 mol/L) than that achievable after
a 1-hour administration of paclitaxel at the maximum tol-
erable dose of 225 mg/m2 in patients with cancer (15
mol/L, Figure 3).12
As defined by Collins13 and Dedrick,14 the pharmacoki-
netic advantage for regional delivery (Rd) of chemothera-
peutic agents can be calculated with the following formula:
Rd  (AUCL/AUCP)1/(AUCL/AUCP)2,
where L1 and P1 refer to lung and plasma values observed
during regional drug delivery (in this case isolated lung
Figure 3. Representative sections of perfused and contralateral, nonperfused lung parenchyma (A and B, respec-
tively) from a sheep receiving 800 mg of paclitaxel by means of isolated lung perfusion.
TABLE 3. Plasma paclitaxel concentrations (g/mL) during and after perfusion or intravenous infusion
Perfusion Intravenous infusion
Time (h) 40 mg 200 mg 200 mg 800 mg 800 mg Time (h) 200 mg
0.08 BLQ BLQ BLQ BLQ BLQ 0.5 6.49
0.5 BLQ BLQ BLQ BLQ BLQ 0.75 8.23
1 BLQ BLQ BLQ BLQ BLQ 1 15.11
1.5 BLQ BLQ BLQ BLQ BLQ 1.5 7.57
1.66 BLQ 0.127 0.089 ND 0.038 2 4.94
1.83 BLQ ND 0.052 0.19 ND 2.5 4.09
2 BLQ ND ND 0.12 ND 3 3.05
2.5 BLQ 0.023 0.027 0.06 0.18 3.5 2.9
4.5 BLQ BLQ BLQ 0.016 0.06 4 2.37
4.5 1.78
5 1.78
6 1.31
7 1.05
BLQ, Below limits of quantitation; ND, not determined.
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perfusion), and L2 and P2 refer to values obtained after
intravenous administration. Using the data from the 200-mg
perfusion and 200-mg intravenous infusion experiments
(Tables 1, 2, and 3), and assuming that the AUC was less
than 0.1 for the plasma during the perfusion (no detectable
levels of paclitaxel were recorded),
Rd  (0.079/0.1)/(0.073/23.06*) 250.
Collectively, these data indicate that paclitaxel can be
administered by means of hyperthermic retrograde isolated
lung perfusion in large animals without obvious immediate
toxicity, and that paclitaxel concentrations in pulmonary
tissues after isolated lung perfusion greatly exceed those
potentially achievable by systemic administration in clinical
settings.
Because moderate hyperthermia is known to enhance the
tumoricidal activity of cytotoxic agents such as melphalan
and cisplatin,15,16 additional experiments were performed to
evaluate the effects of hyperthermia on paclitaxel-mediated
toxicity in cultured cells. Brief hyperthermia (analogous to
what was achieved during isolated lung perfusion) signifi-
cantly enhanced paclitaxel-mediated toxicity in all cancer
cells. The effects were most dramatic in lines established
from melanomas and sarcomas, which typically are refrac-
tory to paclitaxel,17,18 and no toxicity was observed after
paclitaxel exposure under normothermic or hyperthermic
conditions in normal human bronchial epithelial cells (Fig-
ures 4 and 5).
Discussion
Delivery of chemotherapeutic agents via selective lung per-
fusion is an attractive means to control unresectable neo-
plasms or prevent recurrence after pulmonary metastasec-
tomy. Techniques for isolated lung perfusion were
described by Jacobs and colleagues19 and Pierpont and
Blades20 nearly 40 years ago. However, the role of isolated
lung perfusion in cancer therapeutics has not been estab-
lished, primarily because of the invasiveness of the proce-
dure, and the lack of specificity regarding uptake and cyto-
toxicity of the chemotherapeutic agents used to date.5
Furthermore, antegrade perfusion techniques may not be
optimal for drug delivery to pulmonary neoplasms which
frequently derive their blood supply from the bronchial
circulation21,22; indeed, chemotherapeutic agents adminis-
tered by means of selective bronchial artery infusion can
mediate regression of pulmonary neoplasms.23 Conceiv-
ably, retrograde perfusion techniques that exploit collaterals
between pulmonary and bronchial venous systems may
enhance drug delivery to metastatic lesions in the lungs.
Furthermore, use of novel agents that exhibit preferential
cytotoxicity in cancer cells may enhance the efficacy of*AUC 0-4.5 hours.
Figure 4. Paclitaxel 50% inhibitory concentration (IC50) in cultured cancer lines under normothermic or hyperther-
mic conditions.
Figure 5. Effects of paclitaxel in cultured normal human bronchial
epithelial cells under normothermic or hyperthermic conditions.
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isolated lung perfusion, thereby justifying the invasiveness
of this procedure.
In the present study, we sought to determine the potential
of paclitaxel for regional lung delivery. This prototypic
taxane was chosen for study because it induces dose-depend-
ent apoptosis preferentially in cancer cells by a variety of
mechanisms not solely related to microtubule stabiliza-
tion.24-26 In addition, paclitaxel exhibits a broad spectrum of
activity with minimal pulmonary toxicity, even when ad-
ministered systemically at extremely high doses (775-825
mg/m2 over 24 hours) in patients with cancer.17,27 A pro-
tein-free perfusate was used to enhance availability of pac-
litaxel, which is highly protein bound. Our experiments
indicated a disproportional increase of Cmax and AUC of
paclitaxel in lung parenchyma with escalating perfusate
dose, indicating nonlinear, potentially saturable uptake into
lung tissues. The fact that the Cmax and AUC continued to
increase without reaching a plateau indicates that the trans-
port of paclitaxel into lung tissues was not fully saturated,
even with a perfusate dose of 800 mg (320 mol/L). The
calculated regional delivery (Rd) value suggests that the
pulmonary exposure of paclitaxel administration after hy-
perthermic retrograde isolated lung perfusion is 250-fold
more efficient than that achievable by systemic infusion,
thus confirming a profound pharmacokinetic advantage for
paclitaxel administered by means of isolated lung perfusion
techniques. The fact that paclitaxel levels in the systemic
circulation were either undetectable or extremely low after
isolated lung perfusion indicates that some paclitaxel is
retained in the lungs, and that systemic toxicity should be
minimal, despite paclitaxel exposure far in excess of what is
achievable with systemic infusion.
The rationale for considering paclitaxel for administra-
tion by means of isolated lung perfusion is supported by
recent studies indicating that 1-hour paclitaxel infusions can
mediate tumor regressions comparable with those of more
traditional dose regimens but with less toxicity in patients
with solid tumors.28 Maier-Lenz and colleagues12 evaluated
the toxicity and pharmacokinetics of intravenous paclitaxel
administered over 1 hour in 34 patients with incurable
malignancies. Paclitaxel dose was escalated from 150
mg/m2 to 250 mg/m2; dose-limiting neurotoxicity was ob-
served in 2 of 3 patients treated with 250 mg/m2. No
pulmonary toxicity was observed at any dose level. At the
maximum tolerable dose of 225 mg/m2, plasma Cmax was
14.5 g/mL, and AUC was 26 g h/mL; comparable values
were obtained in sheep after a 1-hour infusion of 150 mg/m2
paclitaxel (total dose, 200 mg; Table 3). Much higher values
were readily achieved with hyperthermic retrograde isolated
lung perfusion in these animals.
Potential limitations of this study include the small num-
ber of sheep used for the perfusion experiments and the
absence of intermediate or long-term toxicity data pertain-
ing to these animals. However, our primary objectives were
to determine the feasibility of hyperthermic retrograde iso-
lated lung perfusion and to evaluate the pharmacokinetics of
paclitaxel administered by means of these techniques; as
such, the study was not designed to examine acute or
subacute toxicities related to paclitaxel exposure. Despite
the fact that relatively few animals were used in this study,
pharmacokinetic parameters were quite reproducible within
dose cohorts. Furthermore, no histologic evidence of lung
injury was evident 3 hours after completion of the lung
perfusion at any dose, suggesting that paclitaxel mediates
no immediate toxicities under these exposure conditions.
Clearly, this analysis was insufficient to fully define the
toxicity profile of paclitaxel administered by means of iso-
lated lung perfusion techniques. An institutional review
board–approved, phase I, dose-escalation study is currently
underway to comprehensively evaluate the toxicities and
efficacy of paclitaxel administered by means of hyperther-
mic retrograde isolated lung perfusion in patients with un-
resectable malignant pulmonary tumors.
The clinical formulation of paclitaxel contains 50% cre-
mophor EL, a polyoxyethylated castor oil diluent, and 50%
ethanol, both of which may significantly influence the up-
take and distribution of paclitaxel in pulmonary tissues
during isolated lung perfusion. Cremophor is known to
cause nonlinear pharmacokinetics of paclitaxel during in-
travenous infusion; these effects vary with paclitaxel dose
and infusion duration.29-31 Entrapment of paclitaxel in cre-
mophor micelles can significantly reduce drug availabili-
ty.30 In experiments relevant to our own studies, Knemeyer
and colleagues32 analyzed the effects of chremophor-EL on
urine, bladder tissue, and plasma pharmacokinetics of intra-
vessical paclitaxel. The threshold cremophor concentration
for micelle formation was 0.008%. Ethanol concentrations
up to 1% and cremophor at concentrations below 0.01% did
not alter the free fraction of paclitaxel. Higher concentra-
tions of these diluents, particularly cremophor-EL, signifi-
cantly diminished paclitaxel partitioning across the urothe-
lium, and decreased bladder paclitaxel concentrations, but
did not alter the urine or plasma pharmacokinetics of this
taxane. Interestingly, whereas the intravessical preparation
of paclitaxel facilitated micelle formation with diminished
drug availability, the concentration of cremophor was in-
sufficient to influence distribution of paclitaxel once it had
penetrated into bladder tissue.
The analytic techniques used in our lung perfusion ex-
periments could not discriminate between free and micellar
forms of paclitaxel. In all probability, free paclitaxel mark-
edly diminished as the paclitaxel dose was escalated in the
perfusate. Hence micelle formation may have contributed to
the nonlinear, potentially saturable uptake of paclitaxel into
lung tissues during the perfusion experiments. Nevertheless,
the fact that the Cmax and AUC of paclitaxel in pulmonary
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parenchyma increased in a dose-dependent manner despite
cremophor concentrations greatly exceeding critical micel-
lar concentration in perfusates suggests that a dynamic
equilibrium between tissue and free drug and micellar forms
of paclitaxel in the perfusate facilitated drug uptake into the
lung. Using an ex vivo model system, Creel and col-
leagues33 observed that paclitaxel concentration and perme-
ation distance in arterial tissues increased with perfusate
concentration and exposure duration. Paclitaxel concentra-
tions in the arterial wall greatly exceeded perfusate concen-
trations. Thus interactions with hydrophobic elements
within the blood vessel wall conceivably could enhance
uptake of paclitaxel from lung perfusates and influence the
rate at which paclitaxel moves into extravascular tissues
during isolated lung perfusion. Collectively, these observa-
tions suggest that the pharmacokinetics of paclitaxel admin-
istered by hyperthermic isolated lung perfusion techniques
may be highly complex. The animal model did not allow us
to evaluate the antitumor effects of paclitaxel administered
in this manner.
Although not formally defined, the mechanisms by which
hyperthermia potentiates the cytotoxicity of chemotherapeutic
agents have been attributed to selective dilation of tumor
neovasculature, as well as enhanced drug uptake caused by
increased membrane permeability; these latter effects appear to
be more pronounced in chemoresistant cells.34,35 Rietbroek and
colleagues36 observed no thermal enhancement of paclitaxel
cytotoxicity in R-1 rhabdosarcoma or SW-1573 lung carci-
noma cells in vitro. Leal and coworkers37 reported that high
temperatures (43°C) protected MCF-7 breast cancer cells from
paclitaxel cytotoxicity, despite increased intracellular drug
concentrations. On the other hand, Cividalli and associates38
recently observed that hyperthermia significantly enhanced
paclitaxel cytotoxicity in mouse mammary adenocarcinoma
cells in vivo. Experiments presented in this article clearly
indicate that moderate hyperthermia enhances paclitaxel-me-
diated cytotoxicity in epithelial cancer cells, as well as in
melanoma and sarcoma cells; this phenomenon does not occur
in normal human bronchial epithelial cells after paclitaxel
exposure. These observations may be clinically relevant. Mel-
anomas and sarcomas typically exhibit resistance to tax-
anes.17,18,40 Conceivably, hyperthermia may significantly en-
hance the sensitivity of these malignancies to paclitaxel,
especially when administered by means of regional perfusion
techniques at doses exceeding those achievable by means of
systemic administration. Furthermore, because paclitaxel is a
potent inhibitor of angiogenesis,41,42 the antitumor effects of
this taxane administered under hyperthermic conditions in vivo
may be more pronounced than already suggested by our in
vitro studies. The dramatic pharmacokinetic advantage and
potential therapeutic index of paclitaxel administered by means
of hyperthermic retrograde isolated lung perfusion support
further evaluation of this agent for the regional therapy of
inoperable pulmonary malignancies.
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